Solute carrier transporters as targets for drug delivery and pharmacological intervention for chemotherapy

Journal of Pharmaceutical Sciences

Volumn 100, Issue 9, 2011, Pages 3731-3750

  Nakanishi, Takeo ^a   Tamai, Ikumi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

Author keywords

ABC transporters; Amino acids; Cancer; Chemotherapy; Drug transport; Gene expression; Nutriome; Signal transduction; Slute transporters; Targeted drug delivery

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; 2 MORPHOLINO 8 PHENYLCHROMONE; 4 (4 METHOXYPHENYL) LEVO PHENYLALANYL SARCOSINE; AMINO ACID TRANSPORTER; AMINOPEPTIDASE INHIBITOR; ANTINEOPLASTIC AGENT; ASCT2 PROTEIN; ASPARAGINASE; BACTERIAL ASPARAGINASE; BESTATIN; BETA LACTAM ANTIBIOTIC; CARRIER PROTEIN; CHELERYTHRINE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ESTRONE SULFATE; FLOXURIDINE; FLUOROURACIL; LAT1 PROTEIN; MAMMALIAN TARGET OF RAPAMYCIN; N ACETYL S NITROSOPENICILLAMINE; OLIGOPEPTIDE; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; PEPTIDE DERIVATIVE; PEPTIDE HYDROLASE INHIBITOR; PEPTIDE TRANSPORTER 1; PEPTIDOMIMETIC AGENT; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALACICLOVIR;

BREAST CANCER; CANCER CELL; CANCER CHEMOTHERAPY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG TARGETING; ENZYME SPECIFICITY; GENE EXPRESSION; GENE OVEREXPRESSION; GLIOMA; HORMONE RESPONSE; HUMAN; NONHUMAN; PATHOPHYSIOLOGY; POSITRON EMISSION TOMOGRAPHY; REVIEW; TUMOR GROWTH; UPREGULATION;

EID: 79960140546     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.22576     Document Type: Review

References (187)

1. Nakanishi T. 2007. Drug transporters as targets for cancer chemotherapy. Cancer Genomics Proteomics 4(3):241-254.
2. Gottesman MM, Ling V. 2006. The molecular basis of multidrug resistance in cancer: The early years of P-glycoprotein research. FEBS Lett 580(4):998-1009.
3. Deeley RG, Westlake C, Cole SPC. 2006. Transmembrane transport of endo- and xenobiotics by mammalian ATP-binding cassette multidrug resistance proteins. Physiol Rev 86(3):849-899.
4. Ross DD, Nakanishi T. 2010. Impact of breast cancer resistance protein on cancer treatment outcomes 1st ed., Clifton, NJ: Humana Press, pp 251-290.
5. Tsuji A. 1999. Tissue selective drug delivery utilizing carrier-mediated transport systems. J Control Release 62(1-2):239-244.
6. - symporter (NIS): Imaging and therapeutic applications. Semin Nucl Med 34(1):23-31.
7. Nakanishi T, Tamai I, Takaki A, Tsuji A. 2000. Cancer cell-targeted drug delivery utilizing oligopeptide transport activity. Int J Cancer 88(2):274-280.
8. Ganapathy V, Thangaraju M, Prasad PD. 2009. Nutrient transporters in cancer: Relevance to Warburg hypothesis and beyond. Pharmacol Ther 121(1):29-40.
9. Amann T, Hellerbrand C. 2009. GLUT1 as a therapeutic target in hepatocellular carcinoma. Expert Opin Ther Targets 13(12):1411-1427.
10. Fei Y-J, Kanai Y, Nussberger S, Ganapathy V, Leibach FH, Romero MF, Singh SK, Boron WF, Hediger MA. 1994. Expression cloning of a mammalian proton-coupled oligopeptide transporter. Nature 368(6471):563-566.
11. Miyamoto K, Shiraga T, Morita K, Yamamoto H, Haga H, Taketani Y, Tamai I, Sai Y, Tsuji A, Takeda E. 1996. Sequence, tissue distribution and developmental changes in rat intestinal oligopeptide transporter. Biochim Biophys Acta 1305(1-2):34-38.
12. +/peptide cotransporter family, from human kidney. Biochim Biophys Acta 1235(2):461-466.
13. Sai Y, Tamai I, Sumikawa H, Hayashi K, Nakanishi T, Amano O, Numata M, Iseki S, Tsuji A. 1996. Immunolocalization and pharmacological relevance of oligopeptide transporter PepT1 in intestinal absorption of [beta]-lactam antibiotics. FEBS Lett 392(1):25-29.
14. Tsuji A. 2002. Transporter-mediated drug interactions. Drug Metab Pharmacokinet 17(4):253-274.
15. Tamai I, Nakanishi T, Hayashi K, Terao T, Sai Y, Shiraga T, Miyamoto K, Takeda E, Higashida H, Tsuji A. 1997. The predominant contribution of oligopeptide transporter PepT1 to intestinal absorption of beta-lactam antibiotics in the rat small intestine. J Pharm Pharmacol 49(8):796-801.
16. Balimane PV, Tamai I, Guo A, Nakanishi T, Kitada H, Leibach FH, Tsuji A, Sinko PJ. 1998. Direct evidence for peptide transporter (PepT1)-mediated uptake of a nonpeptide prodrug, valacyclovir. Biochem Biophys Res Commun 250(2):246-251.
17. Kikuchi A, Tomoyasu T, Tanaka M, Kanamitsu K, Sasabe H, Maeda T, Odomi M, Tamai I. 2009. Peptide derivation of poorly absorbable drug allows intestinal absorption via peptide transporter. J Pharm Sci 98(5):1775-1787.
18. +-coupled nutrient carriers coexpressed in the small intestine. J Pharmacol Exp Ther 322(1):220-228.
19. Neumann J, Brandsch M. 2003. δ-Aminolevulinic acid transport in cancer cells of the human extrahepatic biliary duct. J Pharmacol Exp Ther 305(1):219-224.
20. Landowski CP, Vig BS, Song X, Amidon GL. 2005. Targeted delivery to PEPT1-overexpressing cells: Acidic, basic, and secondary floxuridine amino acid ester prodrugs. Mol Cancer Ther 4(4):659-667.
21. Tsume Y, Hilfinger JM, Amidon GL. 2008. Enhanced cancer cell growth inhibition by dipeptide prodrugs of floxuridine: Increased transporter affinity and metabolic stability. Mol Pharm 5(5):717-727.
22. +/peptide transporter. J Nucl Med 49(4):615-622.
23. Mitsuoka K, Kato Y, Miyoshi S, Murakami Y, Hiraiwa M, Kubo Y, Nishimura S, Tsuji A. 2010. Inhibition of oligopeptide transporter suppress growth of human pancreatic cancer cells. Eur J Pharm Sci 40(3):202-208.
24. Sugawara M, Nakanishi T, Fei Y-J, Huang W, Ganapathy ME, Leibach FH, Ganapathy V. 2000. Cloning of an amino acid transporter with functional characteristics and tissue expression pattern identical to that of system A. J Biol Chem 275(22):16473-16477.
25. 0, + and expression of the transporter in tissues amenable for drug delivery. J Pharmacol Exp Ther 308(3):1138-1147.
26. 0, +. J Clin Invest 107(8):1035-1043.
27. 0, +) reveals the potential of the transporter as a drug target for cancer chemotherapy. Biochem J 414(3):343-355.
28. Uchino H, Kanai Y, Kim DK, Wempe MF, Chairoungdua A, Morimoto E, Anders MW, Endou H. 2002. Transport of amino acid-related compounds mediated by L-type amino acid transporter 1 (LAT1): Insights into the mechanisms of substrate recognition. Mol Pharmacol 61(4):729-737.
29. Lin J, Raoof D, Thomas D, Greenson J, Giordano T, Robinson G, Bourner M, Bauer C, Orringer M, Beer D. 2004. L-type amino acid transporter-1 overexpression and melphalan sensitivity in Barrett's adenocarcinoma. Neoplasia 6(1):74-84.
30. Oda K, Hosoda N, Endo H, Saito K, Tsujihara K, Yamamura M, Sakata T, Anzai N, Wempe MF, Kanai Y, Endou H. 2010. l-Type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci 101(1):173-179.
31. McConathy J, Goodman M. 2008. Non-natural amino acids for tumor imaging using positron emission tomography and single photon emission computed tomography. Cancer Metastasis Rev 27(4):555-573.
32. Huang Y, Dai Z, Barbacioru C, Sadée W. 2005. Cystine-glutamate transporter SLC7A11 in cancer chemosensitivity and chemoresistance. Cancer Res 65(16):7446-7454.
33. Gout P, Buckley A, Simms C, Bruchovsky N. 2001. Sulfasalazine, a potent suppressor of lymphoma growth by inhibition of the x(c)- cystine transporter: A new action for an old drug. Leukemia 15(10):1633-1640.
34. Lo M, Ling V, Wang YZ, Gout PW. 2008. The xc- cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance. Br J Cancer 99(3):464-472.
35. Zhang S, Lovejoy KS, Shima JE, Lagpacan LL, Shu Y, Lapuk A, Chen Y, Komori T, Gray JW, Chen X, Lippard SJ, Giacomini KM. 2006. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res 66(17):8847-8857.
36. Yonezawa A, Masuda S, Yokoo S, Katsura T, Inui K. 2006. Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J Pharmacol Exp Ther 319(2):879-886.
37. White DL, Saunders VA, Dang P, Engler J, Zannettino ACW, Cambareri AC, Quinn SR, Manley PW, Hughes TP. 2006. OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): Reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinib. Blood 108(2):697-704.
38. Briz O, Serrano MA, Rebollo N, Hagenbuch B, Meier PJ, Koepsell H, Marin JJG. 2002. Carriers involved in targeting the cytostatic bile acid-cisplatin derivatives cis-diammine-chloro-cholylglycinate-platinum(II) and cis-diammine-bisursodeoxycholate-platinum(II) toward liver cells. Mol Pharmacol 61(4):853-860.
39. Burger H, Zoumaro-Djayoon A, Boersma AWM, Helleman J, Berns E, Mathijssen RHJ, Loos WJ, Wiemer EAC. 2010. Differential transport of platinum compounds by the human organic cation transporter hOCT2 (hSLC22A2). Br J Pharmacol 159(4):898-908.
40. Hu S, Franke RM, Filipski KK, Hu C, Orwick SJ, de Bruijn EA, Burger H, Baker SD, Sparreboom A. 2008. Interaction of imatinib with human organic ion carriers. Clin Cancer Res 14(10):3141-3148.
41. Okabe M, Unno M, Harigae H, Kaku M, Okitsu Y, Sasaki T, Mizoi T, Shiiba K, Takanaga H, Terasaki T, Matsuno S, Sasaki I, Ito S, Abe T. 2005. Characterization of the organic cation transporter SLC22A16: A doxorubicin importer. Biochem Biophys Res Commun 333(3):754-762.
42. Aouida M, Poulin R, Ramotar D. 2010. The human carnitine transporter SLC22A16 mediates high affinity uptake of the anticancer polyamine analogue bleomycin-A5. J Biol Chem 285(9):6275-6284.
43. Ni W, Ji J, Dai Z, Papp A, Johnson AJ, Ahn S, Farley KL, Lin TS, Dalton JT, Li X, Jarjoura D, Byrd JC, Sadee W, Grever MR, Phelps MA. 2010. Flavopiridol pharmacogenetics: Clinical and functional evidence for the role of SLCO1B1/OATP1B1 in flavopiridol disposition. PLoS One 5(11):e13792.
44. van de Steeg E, van Der Kruijssen CMM, Wagenaar E, Burggraaff JEC, Mesman E, Kenworthy KE, Schinkel AH. 2009. Methotrexate pharmacokinetics in transgenic mice with liver-specific expression of human organic anion-transporting polypeptide 1B1 (SLCO1B1). Drug Metab Dispos 37(2):277-281.
45. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I. 2005. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: In vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos 33(3):434-439.
46. Katz DA, Carr R, Grimm DR, Xiong H, Holley-Shanks R, Mueller T, Leake B, Wang Q, Han L, Wang PG, Edeki T, Sahelijo L, Doan T, Allen A, Spear BB, Kim RB. 2006. Organic anion transporting polypeptide 1B1 activity classified by SLCO1B1 genotype influences atrasentan pharmacokinetics. Clin Pharmacol Ther 79(3):186-196.
47. Baker SD, Verweij J, Cusatis GA, van Schaik RH, Marsh S, Orwick SJ, Franke RM, Hu S, Schuetz EG, Lamba V, Messersmith WA, Wolff AC, Carducci MA, Sparreboom A. 2008. Pharmacogenetic pathway analysis of docetaxel elimination. Clin Pharmacol Ther 85(2):155-163.
48. Smith NF, Acharya MR, Desai N, Figg W, Sparreboom A. 2005. Identification of OATP1B3 as a high-affinity hepatocellular transporter of paclitaxel. Cancer Biol Ther 4(8):815-818.
49. Abe T, Unno M, Onogawa T, Tokui T, Noriko Kondo T, Nakagomi R, Adachi H, Fujiwara K, Okabe M, Suzuki T, Nunoki K, Sato E, Kakyo M, Nishio T, Sugita J, Asano N, Tanemoto M, Seki M, Date F, Ono K, Kondo Y, Shiiba K, Suzuki M, Ohtani H, Shimosegawa T, Iinuma K, Nagura H, Ito S, Matsuno S. 2001. LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 120(7):1689-1699.
50. Yamaguchi H, Kobayashi M, Okada M, Takeuchi T, Unno M, Abe T, Goto J, Hishinuma T, Mano N. 2008. Rapid screening of antineoplastic candidates for the human organic anion transporter OATP1B3 substrates using fluorescent probes. Cancer Lett 260(1-2 ):163-169.
51. Nakanishi T, Tamai I, Sai Y, Sasaki T, Tsuji A. 1997. Carrier-mediated transport of oligopeptides in the human fibrosarcoma cell line HT1080. Cancer Res 57(18):4118-4122.
52. Gonzalez DE, Covitz K-MY, Sadée W, Mrsny RJ. 1998. An oligopeptide transporter is expressed at high levels in the pancreatic carcinoma cell lines AsPc-1 and Capan-2. Cancer Res 58(3):519-525.
53. Nakanishi T, Tamai I, Takaki A, Tsuji A. 2000. Cancer cell-targeted drug delivery utilizing oligopeptide transport activity. Int J Cancer 88(2):274-280.
54. Tamai I, Nakanishi T, Nakahara H, Sai Y, Ganapathy V, Leibach FH, Tsuji A. 1998. Improvement of L-dopa absorption by dipeptidyl derivation, utilizing peptide transporter PepT1. J Pharm Sci 87(12):1542-1546.
55. Ogihara H, Suzuki T, Nagamachi Y, Inui K, Takata K. 1999. Peptide transporter in the rat small intestine: Ultrastructural localization and the effect of starvation and administration of amino acids. Histochem J 31(3):169-174.
56. Naruhashi K, Sai Y, Tamai I, Suzuki N, Tsuji A. 2002. PepT1 mRNA expression is induced by starvation and its level correlates with absorptive transport of cefadroxil longitudinally in the rat intestine. Pharm Res 19(10):1417-1423.
57. Shiraga T, Miyamoto K-I, Tanaka H, Yamamoto H, Taketani Y, Morita K, Tamai I, Tsuji A, Takeda E. 1999. Cellular and molecular mechanisms of dietary regulation on rat intestinal H+/peptide transporter PepT1. Gastroenterology 116(2):354-362.
58. Satoh JIN, Tsujikawa T, Fujiyama Y, Bamba T. 2003. Nutritional benefits of enteral alanyl-glutamine supplementation on rat small intestinal damage induced by cyclophosphamide. J Gastroenterol Hepatol 18(6):719-725.
59. Inoue M, Terada T, Okuda M, Inui K. 2005. Regulation of human peptide transporter 1 (PEPT1) in gastric cancer cells by anticancer drugs. Cancer Lett 230(1):72-80.
60. Tanaka H, Miyamoto K, Morita K, Haga H, Segawa H, Shiraga T, Fujioka A, Kouda T, Taketani Y, Hisano S, Fukui Y, Kitagawa K, Takeda E. 1998. Regulation of the PepT1 peptide transporter in the rat small intestine in response to 5-fluorouracil-induced injury. Gastroenterology 114(4):714-723.
61. Thamotharan M, Bawani SZ, Zhou X, Adibi SA. 1999. Hormonal regulation of oligopeptide transporter Pept-1 in a human intestinal cell line. Am J Physiol Cell Physiol 276(4):C821-C826.
62. Nielsen CU, Amstrup J, Nielsen R, Steffansen B, Frokjaer S, Brodin B. 2003. Epidermal growth factor and insulin short-term increase hPepT1-mediated glycylsarcosine uptake in Caco-2 cells. Acta Physiol Scand 178(2):139-148.
63. Rexhepaj R, Rotte A, Pasham V, Gu S, Kempe D, Lang F. 2010. PI3 kinase and PDK1 in the regulation of the electrogenic intestinal dipeptide transport. Cell Physiol Biochem 25(6):715-722.
64. Rexhepaj R, Rotte A, Kempe D, Sopjani M, Föller M, Gehring E-M, Bhandaru M, Gruner I, Mack A, Rubio-Aliaga I, Näßl A-M, Daniel H, Kuhl D, Lang F. 2009. Stimulation of electrogenic intestinal dipeptide transport by the glucocorticoid dexamethasone. Pflügers Arch 459(1):191-202.
65. Izuishi K, Kato K, Ogura T, Kinoshita T, Esumi H. 2000. Remarkable tolerance of tumor cells to nutrient deprivation: Possible new biochemical target for cancer therapy. Cancer Res 60(21):6201-6207.
66. Meissner B, Boll M, Daniel H, Baumeister R. 2004. Deletion of the intestinal peptide transporter affects insulin and TOR signaling in Caenorhabditis elegans. J Biol Chem 279(35):36739-36745.
67. Sato T, Mushiake S, Kato Y, Sato K, Sato M, Takeda N, Ozono K, Miki K, Kubo Y, Tsuji A, Harada R, Harada A. 2007. The Rab8 GTPase regulates apical protein localization in intestinal cells. Nature 448(7151):366-369.
68. Kato Y, Sugiura T, Nakadera Y, Sugiura M, Kubo Y, Sato T, Harada A, Tsuji A. 2009. Investigation of the role of oligopeptide transporter PEPT1 and sodium/glucose cotransporter SGLT1 in intestinal absorption of their substrates using small GTP-binding protein Rab8-null mice. Drug Metab Dispos 37(3):602-607.
69. Palii SS, Chen H, Kilberg MS. 2004. Transcriptional control of the human sodium-coupled neutral amino acid transporter system A gene by amino acid availability is mediated by an intronic element. J Biol Chem 279(5):3463-3471.
70. Fang J, Mao D, Smith CH, Fant ME. 2006. IGF regulation of neutral amino acid transport in the BeWo choriocarcinoma cell line (b30 clone): Evidence for MAP kinase-dependent and MAP kinase-independent mechanisms. Growth Horm IGF Res 16(5-6):318-325.
71. Boehmer C, Okur F, Setiawan I, Bröer S, Lang F. 2003. Properties and regulation of glutamine transporter SN1 by protein kinases SGK and PKB. Biochem Biophys Res Commun 306(1):156-162.
72. Burns KH, Owens GE, Ogbonna SC, Nilson JH, Matzuk MM. 2003. Expression profiling analyses of gonadotropin responses and tumor development in the absence of inhibins. Endocrinology 144(10):4492-4507.
73. Avissar N, Sax H, Toia L. 2008. In human entrocytes, GLN transport and ASCT2 surface expression induced by short-term EGF are MAPK, PI3K, and Rho-dependent. Dig Dis Sci 53(8):2113-2125.
74. Wolfgang CL, Lin C, Meng Q, Karinch AM, Vary TC, Pan M. 2003. Epidermal growth factor activation of intestinal glutamine transport is mediated by mitogen-activated protein kinases. J Gastrointest Surg 7(1):149-156.
75. Pan M, Wolfgang CA, Karinch AM, Lin C, Meng Q, Vary TC, Souba WW. 2002. Protein kinase C activation of intestinal glutamine transport is mediated by mitogen-activated protein kinases. J Surg Res 106(1):137-144.
76. Uchiyama T, Matsuda Y, Wada M, Takahashi S, Fujita T. 2005. Functional regulation of Na+-dependent neutral amino acid transporter ASCT2 by S-nitrosothiols and nitric oxide in Caco-2 cells. FEBS Lett 579(11):2499-2506.
77. Bungard CI, McGivan JD. 2005. Identification of the promoter elements involved in the stimulation of ASCT2 expression by glutamine availability in HepG2 cells and the probable involvement of FXR/RXR dimers. Arch Biochem Biophys 443(1-2):53-59.
78. Laspiur JP, Burton JL, Weber PSD, Moore J, Kirkwood RN, Trottier NL. 2009. Dietary protein intake and stage of lactation differentially modulate amino acid transporter mRNA abundance in porcine mammary tissue. J Nutr 139(9):1677-1684.
79. 0, +) in astrocytes by protein kinase C: Independent effects on raft and non-raft transporter subpopulations. J Neurochem 115(6):1386-1397.
80. Liu XM, Reyna SV, Ensenat D, Peyton KJ, Wang H, Schafer AI, Durante W. 2004. Platelet-derived growth factor stimulates LAT1 gene expression in vascular smooth muscle: Role in cell growth. FASEB J 18(6):768-770.
81. Nii T, Segawa H, Taketani Y, Tani Y, Ohkido M, Kishida S, Ito M, Endou H, Kanai Y, Takeda E, Miyamoto K. 2001. Molecular events involved in upregulating human Na+-independent neutral amino acid transporter LAT1 during T-cell activation. Biochem J 358(3):693-704.
82. Sato H, Tamba M, Kuriyama-Matsumura K, Okuno S, Bannai S. 2000. Molecular cloning and expression of human xCT, the light chain of amino acid transport system xc- Antioxid Redox Signal 2(4):665-671.
83. Kim JY, Kanai Y, Chairoungdua A, Cha SH, Matsuo H, Kim DK, Inatomi J, Sawa H, Ida Y, Endou H. 2001. Human cystine/glutamate transporter: cDNA cloning and upregulation by oxidative stress in glioma cells. Biochim Biophys Acta 1512(2):335-344.
84. - by irinotecan in human head and neck cancer FaDu xenografts. Chemotherapy 56(3):223-233.
85. Peng Q, Warloe T, Berg K, Moan J, Kongshaug M, Giercksky K, Nesland J. 1997. 5-Aminolevulinic acid-based photodynamic therapy. Cancer 79(12):2282-2308.
86. Zopf T, Riemann JF. 1997. The change in laser usage in gastroenterology-The status in 1997. Z Gastroenterol 35(11):987-997.
87. Christensen H. 1989. Distinguishing amino acid transport systems of a given cell or tissue. Methods Enzymol 173:576-616.
88. Souba W. 1993. Glutamine and cancer. Ann Surg 218(6):715-728.
89. Holcenberg J. 2004. Optimal asparaginase therapy. J Pediatr Hematol Oncol 26(5):273-274.
90. Cellarier E, Durando X, Vasson MP, Farges MC, Demiden A, Maurizis JC, Madelmont JC, Chollet P. 2003. Methionine dependency and cancer treatment. Cancer Treat Rev 29(6):489-499.
91. van Sluijters D, Dubbelhuis P, Blommaart E, Meijer A. 2000. Amino-acid-dependent signal transduction. Biochem J 351(3):545-550.
92. Yang Q, Guan K-L. 2007. Expanding mTOR signaling. Cell Res 17(8):666-681.
93. Bjornsti M-A, Houghton PJ. 2004. The tor pathway: A target for cancer therapy. Nat Rev Cancer 4(5):335-348.
94. Wang H, Huang W, Sugawara M, Devoe LD, Leibach FH, Prasad PD, Ganapathy V. 2000. Cloning and functional expression of ATA1, a subtype of amino acid transporter A, from human placenta. Biochem Biophys Res Commun 273(3):1175-1179.
95. Weiss MD, Derazi S, Rossignol C, Varoqui H, Erickson JD, Kilberg MS, Anderson KJ. 2003. Ontogeny of the neutral amino acid transporter SAT1/ATA1 in rat brain. Dev Brain Res 143(2):151-159.
96. Sugawara M, Nakanishi T, Fei Y-J, Martindale RG, Ganapathy ME, Leibach FH, Ganapathy V. 2000. Structure and function of ATA3, a new subtype of amino acid transport system A, primarily expressed in the liver and skeletal muscle. Biochim Biophys Acta 1509(1-2):7-13.
97. Kondoh N, Imazeki N, Arai M, Hada A, Hatsuse K, Masuto H, Matsubara O, Ohkura S, Yamamoto M. 2007. Activation of a system A amino acid transporter, ATA1/SLC38A1, in human hepatocellular carcinoma and preneoplastic liver tissues. Int J Oncol 31(1):81-87.
98. Yu W-l, Cong W-M, Zhang Y, Chen Y, Wang F, Yu G. 2011. Overexpression of ATA1/SLC38A1 predicts future recurrence and death in Chinese patients with hilar cholangiocarcinoma. J Surg Res In Press, Corrected Proof.
99. +-dependent neutral amino acid transporter SNAT2/ATA2 in normal human astrocytes under amino acid starved condition. Neurosci Lett 378(2):70-75.
100. Ling R, Bridges CC, Sugawara M, Fujita T, Leibach FH, Prasad PD, Ganapathy V. 2001. Involvement of transporter recruitment as well as gene expression in the substrate-induced adaptive regulation of amino acid transport system A. Biochim Biophys Acta 1512(1):15-21.
101. Nakanishi T, Kekuda R, Fei Y-J, Hatanaka T, Sugawara M, Martindale RG, Leibach FH, Prasad PD, Ganapathy V. 2001. Cloning and functional characterization of a new subtype of the amino acid transport system N. Am J Physiol Cell Physiol 281(6):C1757-C1768.
102. Chaudhry FA, Reimer RJ, Krizaj D, Barber D, Storm-Mathisen J, Copenhagen DR, Edwards RH. 1999. Molecular analysis of system N suggests novel physiological roles in nitrogen metabolism and synaptic transmission. Cell 99(7):769-780.
103. +-coupled glutamine transporter. J Biol Chem 275(31):23707-23717.
104. Nakanishi T, Sugawara M, Huang W, Martindale RG, Leibach FH, Ganapathy ME, Prasad PD, Ganapathy V. 2001. Structure, function, and tissue expression pattern of human SN2, a subtype of the amino acid transport System N. Biochem Biophys Res Commun 281(5):1343-1348.
105. Sidoryk M, Matyja E, Dybel A, Zielinska M, Bogucki J, Jaskólski DJ, Liberski PP, Kowalczyk P, Albrecht J. 2004. Increased expression of a glutamine transporter SNAT3 is a marker of malignant gliomas. Neuroreort 15(4):575-578.
106. Sidoryk M, Obara M, Albrecht J. 2006. Selective decrease of SN1(SNAT3) mRNA expression in human and rat glioma cells adapted to grow in acidic medium. Neurochem Int 48(6-7):547-552.
107. Fuchs BC, Bode BP. 2005. Amino acid transporters ASCT2 and LAT1 in cancer: Partners in crime? Semin Cancer Biol 15(4):254-266.
108. Fan X, Ross DD, Arakawa H, Ganapathy V, Tamai I, Nakanishi T. 2010. Impact of system L amino acid transporter 1 (LAT1) on proliferation of human ovarian cancer cells: A possible target for combination therapy with anti-proliferative aminopeptidase inhibitors. Biochem Pharmacol 80(6):811-818.
109. Bröer S, Brookes N. 2001. Transfer of glutamine between astrocytes and neurons. J Neurochem 77(3):705-719.
110. 0. Biochem Biophys Res Commun 245(3):824-829.
111. Witte D, Ali N, Carlson N, Younes M. 2002. Overexpression of the neutral amino acid transporter ASCT2 in human colorectal adenocarcinoma. Anticancer Res 22(5):2555-2557.
112. Dolinska M, Dybel A, Zablocka B, Albrecht J. 2003. Glutamine transport in C6 glioma cells shows ASCT2 system characteristics. Neurochem Int 43(4-5):501-507.
113. Sidoryk M, Matyja E, Dybel A, Zielinska M, Bogucki J, Jaskolski DJ, Liverski PP, Kowalczyk P, Albrecht J. 2004. Increased expression of a glutamine transporter SNAT3 is a marker of malignant gliomas. Neuroreport 15(4):575-578.
114. Iannoli P, Miller J, Ryan C, Gu L, Ziegler T, Sax H. 1997. Epidermal growth factor and human growth hormone accelerate adaptation after massive enterectomy in an additive, nutrient-dependent, and site-specific fashion. Surgery 122(4):728-729.
115. Salomon DS, Brandt R, Ciardiello F, Normanno N. 1995. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol/Hematol 19(3):183-232.
116. Biscardi JS, Ishizawar RC, Silva CM, Parson SJ. 2000. Tyrosine kinase signaling in breast cancer epidermal growth factor receptor and c-Src interactions in breast cancer. Breast Cancer Res 2:203-210.
117. Bungard CI, McGivan JD. 2004. Glutamine availability upregulates expression of the amino acid transporter protein ASCT2 in HepG2 cells and stimulates the ASCT2 promoter. Biochem J 382(1):27-32.
118. Fuchs BC, Perez JC, Suetterlin JE, Chaudhry SB, Bode BP. 2004. Inducible antisense RNA targeting amino acid transporter ATB0/ASCT2 elicits apoptosis in human hepatoma cells. Am J Physiol Gastrointest Liver Physiol 286(3):G467-G478.
119. o from a human placental choriocarcinoma cell line. J Biol Chem 271(31):18657-18661.
120. Fuchs BC, Finger RE, Onan MC, Bode BP. 2007. ASCT2 silencing regulates mammalian target-of-rapamycin growth and survival signaling in human hepatoma cells. Am J Physiol Cell Physiol 293(1):C55-C63.
121. 0+. J Biol Chem 274(34):23740-23745.
122. 0, + from mouse colon expressed in HRPE cells and Xenopus oocytes. J Physiol 532(2):297-304.
123. 0, + expressed in the colon. Biochem Biophys Res Commun 291(2):291-295.
124. 0, + (SLC6A14) in colorectal cancer and metastasis in humans. Biochim Biophys Acta 1741(1-2):215-223.
125. 0, + (SLC6A14) in carcinoma of the cervix. Gynecol Oncol 100(1):8-13.
126. Török NJ, Higuchi H, Bronk S, Gores GJ. 2002. Nitric oxide inhibits apoptosis downstream of cytochrome c release by nitrosylating caspase 9. Cancer Res 62(6):1648-1653.
127. Morbidelli L, Donnini S, Ziche M. 2004. Role of nitric oxide in tumor angiogenesis. Cancer Treat Res 117:155-167.
128. Lagares-Garcia J, Moore R, Collier B, Heggere M, Diaz F, Qian F. 2001. Nitric oxide synthase as a marker in colorectal carcinoma. Am Surg 67(7):709-713.
129. BBe1 cells. J Nutr 135(1):14-18.
130. Babu E, Kanai Y, Chairoungdua A, Kim DK, Iribe Y, Tangtrongsup S, Jutabha P, Li Y, Ahmed N, Sakamoto S, Anzai N, Nagamori S, Endou H. 2003. Identification of a novel system L amino acid transporter structurally distinct from heterodimeric amino acid transporters. J Biol Chem 278(44):43838-43845.
131. Bodoy S, Marrtín L, Zorzano A, Palacín M, Estévez R, Bertran J. 2005. Identification of LAT4, a novel amino acid transporter with system L activity. J Biol Chem 280(12):12002-12011.
132. Verrey F, Closs E, Wagner C, Palacin M, Endou H, Kanai Y. 2004. CATs and HATs: The SLC7 family of amino acid transporters. Pflügers Arch 447(5):532-542.
133. Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, Cha SH, Matsuo H, Fukushima J-I, Fukasawa Y, Tani Y, Taketani Y, Uchino H, Kim JY, Inatomi J, Okayasu I, Miyamoto K-I, Takeda E, Goya T, Endou H. 2001. Human L-type amino acid transporter 1 (LAT1): Characterization of function and expression in tumor cell lines. Biochim Biophys Acta 1514(2):291-302.
134. Wolf D, Wang S, Panzica M, Bassily N, Thompson N. 1996. Expression of a highly conserved oncofetal gene, TA1/E16, in human colon carcinoma and other primary cancers: Homology to Schistosoma mansoni amino acid permease and Caenorhabditis elegans gene products. Cancer Res 56(21):5012-5022.
135. Nawashiro H, Otani N, Shinomiya N, Fukui S, Ooigawa H, Shima K, Matsuo H, Kanai Y, Endou H. 2006. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 119(3):484-492.
136. Kobayashi H, Ishii Y, Takayama T. 2005. Expression of L-type amino acid transporter 1 (LAT1) in esophageal carcinoma. J Surg Oncol 90(4):233-238.
137. Sakata T, Ferdous G, Tsuruta T, Satoh T, Baba S, Muto T, Ueno A, Kanai Y, Endou H, Okayasu I. 2009. L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int 59(1):7-18.
138. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Nakajima T, Mori M. 2009. Prognostic significance of l-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (CD98) expression in stage I pulmonary adenocarcinoma. Lung Cancer 66(1):120-126.
139. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Tanaka S, Ishizuka T, Kanai Y, Endou H, Nakajima T, Mori M. 2008. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 98(4):742-748.
140. Kanai Y, Segawa H, Miyamoto K-I, Uchino H, Takeda E, Endou H. 1998. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 273(37):23629-23632.
141. Prasad PD, Wang H, Huang W, Kekuda R, Rajan DP, Leibach FH, Ganapathy V. 1999. Human LAT1, a subunit of system L amino acid transporter: Molecular cloning and transport function. Biochem Biophys Res Commun 255(2):283-288.
142. Yamauchi K, Sakurai H, Kimura T, Wiriyasermkul P, Nagamori S, Kanai Y, Kohno N. 2009. System L amino acid transporter inhibitor enhances anti-tumor activity of cisplatin in a head and neck squamous cell carcinoma cell line. Cancer Lett 276(1):95-101.
143. Schmelzle T, Hall MN. 2000. TOR, a central controller of cell growth. Cell 103(2):253-262.
144. Cohen A, Hall MN. 2009. An amino acid shuffle activates mTORC1. Cell 136(3):399-400.
145. Chatila T, Silverman L, Miller R, Geha R. 1989. Mechanisms of T cell activation by the calcium ionophore ionomycin. J Immunol 143(4):1283-1289.
146. Fan Q-W, Cheng C, Knight ZA, Haas-Kogan D, Stokoe D, James CD, McCormick F, Shokat KM, Weiss WA. 2009. EGFR signals to mTOR through PKC and independently of Akt in glioma. Sci Signal 2(55):ra4.
147. Boado RJ, Li JY, Tsukamoto H, Pardridge WM. 2003. Hypoxia induces de-stabilization of the LAT1 large neutral amino acid transporter mRNA in brain capillary endothelial cells. J Neurochem 85(4):1037-1042.
148. Shennan DB, Thomson J. 2008. Inhibition of system L (LAT1/CD98hc) reduces the growth of cultured human breast cancer cells. Oncol Rep 20(4):885-889.
149. Kim CS, Cho S-H, Chun HS, Lee S-Y, Endou H, Kanai Y, Kim DK. 2008. BCH, an inhibitor of system L amino acid transporters, induces apoptosis in cancer cells. Biol Pharm Bull 31(6):1096-1100.
150. Krige D, Needham LA, Bawden LJ, Flores N, Farmer H, Miles LEC, Stone E, Callaghan J, Chandler S, Clark VL, Kirwin-Jones P, Legris V, Owen J, Patel T, Wood S, Box G, Laber D, Odedra R, Wright A, Wood LM, Eccles SA, Bone EA, Ayscough A, Drummond AH. 2008. CHR-2797: An antiproliferative aminopeptidase inhibitor that leads to amino acid deprivation in human leukemic cells. Cancer Res 68(16):6669-6679.
151. Hosoya K, Kyoko H, Toyooka N, Kato A, Orihashi M, Tomi M, Tachikawa M. 2008. Evaluation of amino acid-mustard transport as L-type amino acid transporter 1 (LAT1)-mediated alkylating agents. Biol Pharm Bull 31(11):2126-2130.
152. Nabeyama A, Kurita A, Asano K, Miyake Y, Yasuda T, Miura I, Nishitai G, Arakawa S, Shimizu S, Wakana S, Yoshida H, Tanaka M. 2010. xCT deficiency accelerates chemically induced tumorigenesis. Proc Natl Acad Sci USA 107(14):6436-6441.
153. - cystine/glutamate antiporter: A potential target for therapy of cancer and other diseases. J Cell Physiol 215(3):593-602.
154. - cystine/glutamate antiporter as a potential therapeutic target for small-cell lung cancer: Use of sulfasalazine. Cancer Chemother Pharmacol 64(3):463-472.
155. Okuno S, Sato H, Kuriyama-Matsumura K, Tamba M, Wang H, Sohda S, Hamada H, Yoshikawa H, Kondo T, Bannai S. 2003. Role of cystine transport in intracellular glutathione level and cisplatin resistance in human ovarian cancer cell lines. Br J Cancer 88(6):951-956.
156. Jonker JW, Schinkel AH. 2004. Pharmacological and physiological functions of the polyspecific organic cation transporters: OCT1, 2, and 3 (SLC22A1-3). J Pharmacol Exp Ther 308(1):2-9.
157. Pandor A, Eggington S, Paisley S, Tappenden P, Sutcliffe P. 2006. The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: Systematic review and economic evaluation. Health Technol Assess 10(41):1-185.
158. White DL, Dang P, Engler J, Frede A, Zrim S, Osborn M, Saunders VA, Manley PW, Hughes TP. 2010. Functional activity of the OCT-1 protein Is predictive of long-term outcome in patients with chronic-phase chronic myeloid leukemia treated with imatinib. J Clin Oncol 28(16):2761-2767.
159. Wang L, Giannoudis A, Lane S, Williamson P, Pirmohamed M, Clark RE. 2007. Expression of the uptake drug transporter hOCT1 is an important clinical determinant of the response to imatinib in chronic myeloid leukemia. Clin Pharmacol Ther 83(2):258-264.
160. + cells have reduced uptake of imatinib due to low OCT-1 activity. Leukemia 24(4):765-770.
161. Shnitsar V, Eckardt R, Gupta S, Grottker J, Müller GA, Koepsell H, Burckhardt G, Hagos Y. 2009. Expression of human organic cation transporter 3 in kidney carcinoma cell lines increases chemosensitivity to melphalan, irinotecan, and vincristine. Cancer Res 69(4):1494-1501.
162. Peluso G, Nicolai R, Reda E, Benatti P, Barbarisi A, Calvani M. 2000. Cancer and anticancer therapy-induced modifications on metabolism mediated by carnitine system. J Cell Physiol 182(3):339-350.
163. Tamai I, Yabuuchi H, Nezu J, Sai Y, Oku A, Shimane M, Tsuji A. 1997. Cloning and characterization of a novel human pH-dependent organic cation transporter, OCTN1. FEBS Lett 419(1):107-111.
164. Tamai I, Ohashi R, Nezu J-i, Yabuuchi H, Oku A, Shimane M, Sai Y, Tsuji A. 1998. Molecular and functional identification of sodium ion-dependent, high affinity human carnitine transporter OCTN2. J Biol Chem 273(32):20378-20382.
165. Rytting E, Audus KL. 2007. Effects of low oxygen levels on the expression and function of transporter OCTN2 in BeWo cells. J Pharm Pharmacol 59(8):1095-1102.
166. Enomoto A, Wempe MF, Tsuchida H, Shin HJ, Cha SH, Anzai N, Goto A, Sakamoto A, Niwa T, Kanai Y, Anders MW, Endou H. 2002. Molecular identification of a novel carnitine transporter specific to human testis. J Biol Chem 277(39):36262-36271.
167. Gong S, Lu X, Xu Y, Swiderski CF, Jordan CT, Moscow JA. 2002. Identification of OCT6 as a novel organic cation transporter preferentially expressed in hematopoietic cells and leukemias. Exp Hematol 30(10):1162-1169.
168. Hagenbuch B, Meier P. 2004. Organic anion transporting polypeptides of the OATP/SLC21 family: Phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflügers Arch 447(5):653-665.
169. Tamai I, Nezu J-i, Uchino H, Sai Y, Oku A, Shimane M, Tsuji A. 2000. Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem Biophys Res Commun 273(1):251-260.
170. Hagenbuch B, Meier PJ. 2003. The superfamily of organic anion transporting polypeptides. Biochim Biophys Acta 1609(1):1-18.
171. Hagenbuch B, Gui C. 2008. Xenobiotic transporters of the human organic anion transporting polypeptides (OATP) family. Xenobiotica 38(7-8):778-801.
172. Abe T, Kakyo M, Tokui T, Nakagomi R, Nishio T, Nakai D, Nomura H, Unno M, Suzuki M, Naitoh T, Matsuno S, Yawo H. 1999. Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J Biol Chem 274(24):17159-17163.
173. Wang X, Wolkoff AW, Morris ME. 2005. Flavonoids as a novel class of human organic anion-transporting polypeptide OATP1B1 (OATP-C) modulators. Drug Metab Dispos 33(11):1666-1672.
174. Hirano M, Maeda K, Shitara Y, Sugiyama Y. 2004. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311(1):139-146.
175. *15 genotypes after irinotecan-based chemotherapy. Cancer Chemother Pharmacol 63(6):1165-1169.
176. Okabe M, Szakacs G, Reimers MA, Suzuki T, Hall MD, Abe T, Weinstein JN, Gottesman MM. 2008. Profiling SLCO and SLC22 genes in the NCI-60 cancer cell lines to identify drug uptake transporters. Mol Cancer Ther 7(9):3081-3091.
177. Letschert K, Keppler D, König J. 2004. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 14(7):441-452.
178. Hamada A, Sissung T, Price DK, Danesi R, Chau CH, Sharifi N, Venzon D, Maeda K, Nagao K, Sparreboom A, Mitsuya H, Dahut WL, Figg WD. 2008. Effect of SLCO1B3 haplotype on testosterone transport and clinical outcome in caucasian patients with androgen-independent prostatic cancer. Clin Cancer Res 14(11):3312-3318.
179. Muto M, Onogawa T, Suzuki T, Ishida T, Rikiyama T, Katayose Y, Ohuchi N, Sasano H, Abe T, Unno M. 2007. Human liver-specific organic anion transporter-2 is a potent prognostic factor for human breast carcinoma. Cancer Sci 98(10):1570-1576.
180. Lee W, Belkhiri A, Lockhart AC, Merchant N, Glaeser H, Harris EI, Washington MK, Brunt EM, Zaika A, Kim RB, El-Rifai W. 2008. Overexpression of OATP1B3 confers apoptotic resistance in colon cancer. Cancer Res 68(24):10315-10323.
181. Nozawa T, Suzuki M, Takahashi K, Yabuuchi H, Maeda T, Tsuji A, Tamai I. 2004. Involvement of estrone-3-sulfate transporters in proliferation of hormone-dependent breast cancer cells. J Pharmacol Exp Ther 311(3):1032-1037.
182. Nozawa T, Suzuki M, Yabuuchi H, Irokawa M, Tsuji A, Tamai I. 2005. Suppression of cell proliferation by inhibition of estrone-3-sulfate transporter in estrogen-dependent breast cancer cells. Pharm Res 22(10):1634-1641.
183. Wlcek K, Svoboda M, Sellner F, Krupitza G, Jaeger W, Thalhammer T. 2008. Altered expression of organic anion transporter polypeptide (OATP) genes in human breast carcinoma. Cancer Biol Ther 7(9):1450-1455.
184. Meyer zu Schwabedissen HE, Tirona RG, Yip CS, Ho RH, Kim RB. 2008. Interplay between the nuclear receptor pregnane X receptor and the uptake transporter organic anion transporter polypeptide 1A2 selectively enhances estrogen effects in breast cancer. Cancer Res 68(22):9338-9347.
185. Maeda T, Irokawa M, Arakawa H, Kuraoka E, Nozawa T, Tateoka R, Itoh Y, Nakanishi T, Tamai I. 2010. Uptake transporter organic anion transporting polypeptide 1B3 contributes to the growth of estrogen-dependent breast cancer. J Steroid Biochem Mol Biol 122(4):180-185.
186. Al SW, Mokbel R, Salhab M, Jiang W, Reed M, Mokbel K. 2006. The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer. Anticancer Res 26(6C):4985-4990.
187. Bronger H, König J, Kopplow K, Steiner H-H, Ahmadi R, Herold-Mende C, Keppler D, Nies AT. 2005. ABCC drug efflux pumps and organic anion uptake transporters in human gliomas and the blood-tumor barrier. Cancer Res 65(24):11419-11428.